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Abstract
Background: Treatment of non-union remains challenging and often necessitates augmentation of the resulting
defect with an autologous bone graft (ABG). ABG is limited in quantity and its harvesting incurs an additional
surgical intervention leaving the risk for associated complications and morbidities. Therefore, artificial bone graft
substitutes that might replace autologous bone are needed. S53P4-type bioactive glass (BaG) is a promising
material which might be used as bone graft substitute due to its osteostimulative, conductive and antimicrobial
properties. In this study, we plan to examine the clinical effectiveness of BaG as a bone graft substitute in
Masquelet therapy in comparison with present standard Masquelet therapy using an ABG with tricalciumphosphate
to fill the bone defect.
Methods/design: This randomized controlled, clinical non-inferiority trial will be carried out at the Department of
Orthopedics and Traumatology at Heidelberg University. Patients who suffer from tibial or femoral non-unions with
a segmental bone defect of 2–5 cm and who are receiving Masquelet treatment will be included in the study. The
resulting bone defect will either be filled with autologous bone and tricalciumphosphate (control group, N = 25) or
BaG (S53P4) (study group, N = 25). Subsequent to operative therapy, all patients will receive the same standardized
follow-up procedures. The primary endpoint of the study is union achieved 1year after surgery.
Discussion: The results from the current study will help evaluate the clinical effectiveness of this promising
biomaterial in non-union therapy. In addition, this randomized trial will help to identify potential benefits and
limitations regarding the use of BaG in Masquelet therapy. Data from the study will increase the knowledge about
BaG as a bone graft substitute as well as identify patients possibly benefiting from Masquelet therapy using BaG
and those who are more likely to fail, thereby improving the quality of non-union treatment.
Trial registration: German Clinical Trials Register (DRKS), ID: DRKS00013882. Registered on 22 January 2018.
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Background
Fracture healing is a complex physiological process
dependent on the intricate interaction of numerous part-
ners [1]. Delayed or failed fracture healing can lead to
enormous limitations in the quality of life due to pain,
reduced mobility, and considerably longer duration of
disease. In addition, non-union of a fracture can also
lead to debilitating economic and social circumstances
[2]. Despite recent research advances and modern treat-
ment options, up to 30% of long bone fractures develop
non-unions [1, 3, 4]. Especially the treatment of atrophic
and infected non-unions, as well as large defect sizes, re-
mains a challenge in trauma and orthopedic surgery.
Treatment of segmental defects can be divided into two
general categories: (1). bone transport and (2). bone fill-
ing [5, 6]. In defects larger than 4–6 cm in length the
“gold standard” remains bone transport [6]; whereas, in
segmental defects of between 2- to 5-cm bone filling has
shown good clinical and radiological outcomes [5, 6].
Therefore, the induced membrane technique, also
known as the Masquelet technique, was established [7–
11]. It is a two-staged procedure; during the first step a
vascularized membrane, containing growth factors and
supporting the proliferation of human bone marrow
stromal cells, is induced via a foreign-body reaction [7].
The second step involves surgically augmenting the
membranous tube via an ABG, due to its osteostimula-
tive and osteoconductive properties as well as its osteo-
genic potential [8, 10]. The most frequently accessed
donor site remains the iliac crest. However, complica-
tions, such as donor-site morbidity, pain and quantita-
tive limitations, are well-documented [12–15]. In recent
years, the reamer/irrigator/aspirator (RIA) system has
shown numerous advantages in harvesting autologous
bone from the medullary canal of long bones [16].
Reaming debris became a reliable alternative as a source
for autologous bone and the RIA system has shown de-
creased morbidity at the harvest site and none of the
complications of the iliac crest site [17–21]. From a cel-
lular aspect, mesenchymal stem cells harvested by the
RIA system show significantly superior osteogenic differ-
entiation and higher sensitivity towards stimulation with
differentiation factors compared to mesenchymal stem
cells isolated from iliac crest bone marrow [22, 23].
Evaluation of the outcome of non-union therapy re-
mains challenging. A standardized approach was estab-
lished by recent studies [11, 24] containing both
radiological and clinical parameters. Clinical outcome
can be determined via assessment of mechanical stabil-
ity, pain associated with weight-bearing and the subject-
ive health of patients [24]. Standard of care in the
radiological assessment of bone healing and consolida-
tion of non-union subsequent to treatment remains peri-
odical conventional x-rays of the affected bone [11, 24–
26]. Radiological union can be assumed when bridging
of three out of four cortices is apparent. However, evalu-
ation of osseous consolidation of non-unions relying
merely on x-rays can be misleading. In a recent study by
Akiho et al. [25] the authors compared conventional
x-rays and computed tomography (CT) scans of pubic
bone non-unions. Their data showed that CT scans were
able to identify a larger number of delayed unions. Thus,
even when osseous consolidation is presumed on x-ray,
where there are numerous layers superimposed upon
one another in both planes, persistent non-unions can
only be detected reliably via CT scans [25]. However,
utilization of CT scans is limited due to their higher ra-
diation exposure. Therefore, a combination of both
methods is beneficial to assess radiological outcome of
non-union treatment. Promising new diagnostic modal-
ities contributing to a timely identification of successful
non-union treatment have been introduced in recent
years. In particular, analysis of serum cytokine expres-
sion pattern was established as a valid method in the
evaluation of the biological processes occurring during
bone regeneration [27, 28]. In addition, dynamic
contrast-enhanced magnetic resonance imaging
(DCE-MRI) perfusion analysis after non-union treatment
was able to successfully predict the outcome of
non-union therapy [29]. Furthermore, the combination
of DCE-MRI and contrast enhanced ultrasound (CEUS)
was able to distinguish between infected and aseptic
non-unions pre-operatively [30]. Hence, a combination
of standardized and innovative diagnostic modalities
contributes to a precise and timely identification of suc-
cessful non-union treatment and, furthermore, helps
identify patients at risk for infected non-unions.
Regardless of the source, harvesting of autologous
bone necessitates an additional surgical intervention
with a potential risk for associated complications and
morbidities. Also, in some patients, either harvesting of
autologous bone via RIA is anatomically impossible or
they may have already have had both iliac crests de-
pleted, or both may apply. Hence, alternative methods,
such as allogenic bone, demineralized bone matrix and
biomaterials designed as artificial bone graft substitutes,
have been extensively studied, but found to be lacking in
comparison to an ABG [31, 32]. In order to replace the
ABG, the substituting biomaterial must be bioactive (the
effect of the materials on cells that activate specific re-
sponses), degradable, osteoconductive and osteostimula-
tive [33, 34]. BaG (S53P4) is such a material and is
currently used as bone graft substitute and in the treat-
ment of osteomyelitis [33]. BaG has osteostimulative
properties; the release of calcium ions leads to formation
of hydroxyapatite. It is also osteoconductive, serving as a
scaffold for bone formation in vivo [33]. In addition,
BaG has been shown to have antimicrobial properties
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due to its release of ions from its surface resulting in an
increasing osmotic pressure and pH leading to a micro-
environment unsuitable for microbial growth [35].
Therefore, S53P4-type BaG (53% SiO2, 4% P2O5, 23%
Na2O and 20% CaO in wt%) is a promising material to
employ as bone graft substitute in context with
non-union therapy.
The current study is a randomized controlled trial
(RCT) regarding the non-inferiority of the effectiveness
and safety of the use of BaG (S53P4) as bone graft sub-
stitute in Masquelet therapy for treating
large-sized-defect non-unions of the tibia and femur in
comparison to the standard therapy. The study protocol
for the RCT is described in the present manuscript.
Methods/design
Objectives
The primary objective of this study is to evaluate the
non-inferiority of the clinical effectiveness of BaG as a
bone graft substitute in Masquelet therapy when com-
pared to present standard Masquelet therapy using an
ABG in combination with ceramic bone substitutes,
such as tricalciumphosphates, to fill the bone defect.
Secondary objectives include subjective patient quality of
life directly post-operative as well as during the time of
recovery, documentation of perfusion of the bone graft
using CEUS as well as DCE-MRI [26, 29]. Furthermore,
patient data (such as smoking status, drug abuse, profes-
sion, time necessary to return to work and pre-existing
condition) will be assessed and evaluated. Therefore, the
results from the current study will facilitate the evalu-
ation of BaG as a bone graft substitute regarding object-
ive parameters associated with consolidation as well as
subjective parameters associated with the patients’ qual-
ity of life. Furthermore, patients who are at risk for un-
successful treatment with one or the other approach
might be identified. Hence, results from the study will
contribute to thoroughly assess whether BaG is a suit-
able bone graft substitute in non-union therapy using
the Masquelet method.
Study design
This is a registered, prospective, single-center, two-arm,
parallel-group, randomized controlled non-inferiority
trial (DRKS00013882).
Inclusion and exclusion criteria
Patients older than 18 years who suffer from tibial or
femoral non-unions with a segmental bone defect of 2–
5 cm and who are receiving Masquelet treatment will be
included into the study after giving informed consent.
Patients who do not agree to participate in the study,
who are not applicable for harvesting autologous bone
using the RIA system, who are not able to give informed
consent and patients receiving an amputation because of
persistent infection or extended soft tissue defects will
be excluded from the study.
Setting
The study is carried out at the Department of Orthope-
dics and Traumatology at Heidelberg University (level 1
trauma center). Surgical treatment of non-union is
established and a standardized follow-up setting is devel-
opment to monitor response to the treatment and clin-
ical consolidation [4, 11, 24].
Randomization
Due to the sample size a block randomization procedure
with randomly chosen block sizes is used to assign par-
ticipants to each group (1:1 ratio), resulting in one inter-
vention and one control group. This method helps in
maintaining the balance of treatment assignment while
reducing the potential for selection bias [36].
Randomization is performed by an employee not in-
volved in treatment, assessment or data collection re-
garding the present study using opaque, sealed
envelopes.
Surgical treatment
After information and randomization, all patients receive
contrast-enhanced ultrasound sonography (CEUS)
pre-operatively to evaluate local perfusion. Hereafter,
they are scheduled for Masquelet therapy of the
non-union. Masquelet therapy is based on the principles
of the “diamond concept” [37] and is a two-step proced-
ure (step I and step II). During the first step, radical de-
bridement of the non-union, non-viable bone and
surrounding tissue is performed [38]. The resulting seg-
mental bone defect is subsequently filled with poly-
methylmethacrylate (PMMA), which induces a
foreign-body reaction, resulting in a vascularized Mas-
quelet membrane [7]. In addition, multiple bone and soft
tissue samples are harvested for microbiological examin-
ation. The first step is repeated until all samples are ster-
ile. Once sterile, the spacer is left in situ for 6 weeks to
guarantee a fully grown Masquelet membrane [7, 10]. In
a second step the spacer is removed while leaving the
membrane unimpaired and the resulting bone defect
filled with either autologous bone and tricalcium phos-
phate (control group) or BaG (S53P4) (study group).
Due to the decreased morbidity at the harvest site and
significantly superior osteogenic differentiation and
higher sensitivity towards stimulation with differenti-
ation factors harvesting of autologous bone graft will be
performed with the RIA system [39]. However, if the
quantity of the reaming material threatens to be insuffi-
cient, additional harvesting of the iliac crest might be
necessary to achieve sufficient filling of the osseous
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defect. De novo osteosynthesis utilizing plates, nails or
external fixators is performed depending on the bio-
mechanical stability during the first or second step of
the Masquelet therapy. The eligibility of the utilized
method of osteosynthesis will be based on anatomical
premises as well as morphology of the non-union and
will be carefully evaluated pre-operatively. A flow chart
of the surgical treatment is depicted in Fig. 1.
Post-operatively, all patients regardless of the method of
fixation will be treated with partial weight-bearing of
20 kg for 6 weeks; afterwards patients will gradually in-
crease weight-bearing with approximately 10 kg per
week until full weight-bearing is achieved.
Follow-up
Subsequent to the operative therapy, all patients will re-
ceive the same follow-up procedures. Follow-up at our
institution is standardized and all procedures and diag-
nostics are based solely on medical indications. Initial
radiological and clinical evaluation of the surgical treat-
ment will be performed on day 2 after surgery.
Discharge from the hospital will be realized as soon as
soft tissue conditions, patient mobility and pain level
allow it. Afterwards, patients will receive physiotherapy
on a regular basis of at least twice a week. Clinical and
radiological follow-up visits at our hospital are planned
at 6 weeks, 3, 6, 9, 12 and 24 months post-operatively,
following the standardized procedure for non-union pa-
tients treated in our hospital (see Table 1) [27]. By using
a questionnaire pre-operatively and post-operatively
after 3, 12 and 24 months, patients can give information
on pain, mobility of limbs and life quality (SF-12) during
the course of treatment. General patient data, such as
profession, Body Mass Index (BMI), risk factors, medica-
tion, pre-existing conditions, previous surgeries and ac-
cident data will be obtained pre-operatively. Subsequent
to step II, the outcome of therapy will be evaluated
based on clinical and radiological examination. Potential
for vascularization will be evaluated pre-operatively and
at 12 weeks subsequent to step II via CEUS using the
established protocol [26]. After 12 weeks, patients also
receive DCE-MRI to assess vitality of the graft as a
Fig. 1 Flow chart of the Masquelet therapy and treatment pattern of included patients
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previous study has shown that DCE-MRI perfusion ana-
lysis after non-union surgery predicts successful out-
come [29].
After 12 months, a CT of the affected bone will be per-
formed to further evaluate osseous consolidation. Patients
in both study groups will be declared responder/non-re-
sponder due to radiological signs of consolidation and clin-
ical signs of mechanical stability and full weight-bearing.
Furthermore, blood samples will be obtained during the
course of treatment and analyzed regarding parameters of
infection, growth factors and cytokines associated with
angiogenesis. Previous studies have shown that analysis of
serological cytokine expression pattern is a valid tool in
evaluation of the potential for angiogenesis and effective-
ness for additional non-union therapy [27, 28]. After 12
and 24 months, results of the groups will be statistically an-
alyzed and compared. Duration of patient enrollment will
be 2 years. Data will be stored and monitored using pseu-
donyms. Only PH and MCT have access to the full names
of the participants. Follow-up will be 2 years with data ana-
lysis after 1 year and 2 years. The duration of the study is 4
years (Table 1).
Primary outcome measure
The primary endpoint of the study is union achieved 1
year after surgery by evaluation of x-rays in two planes
(defined as cortical bridging of at least three out of four
cortices) and CT scan [40]. The radiographic datasets
will be blinded and evaluated by a group of experienced
orthopedic surgeons.
Secondary outcome measure
Secondary endpoints include subjective evaluation of the
quality of life (assessed by the 12-item Short Form
health survey (SF-12) questionnaire) and pain (Visual
Analog Scale (VAS) of affected patients. In addition, per-
fusion of the graft is evaluated using CEUS and
DCE-MRI and compared between groups. Expression
patterns of inflammatory and angiogenic cytokines are
evaluated during the course of the study and compared
between groups regarding possible differences. Addition-
ally, union achieved 2 years after surgery will be
evaluated based on x-rays in two planes (defined as cor-
tical bridging of at least three out of four cortices) and
possible differences regarding socioeconomic factors
(time necessary to return to work, time of recovery) are
assessed and compared between groups.
Criteria that lead to termination of study
Data of included patient will be continuously monitored
regarding outcome and unexpected risk for participating
patients. If initial data indicates either an inferior out-
come of patients included into the study group, or an in-
creased risk for patients of the study group that is
potentially harmful for patients, the study will be termi-
nated. Furthermore, if patients want to withdraw their
consent to the study, they will be excluded from the
current study. Withdrawal from the study will not im-
pact the quality of the medical treatment of patients.
Statistical analysis
Statistical calculation will be conducted with R version 3.4.3
[41], figures will be created using the package “ggplot2”
[42]. Receiver operator characteristics analysis will be per-
formed via the “pROC” package [43]. Correlation analyses
will be performed between all variables. Non-parametric
tests (Mann-Whitney U test for independent variables, Wil-
coxon signed-rank test for dependent variables) will be uti-
lized to investigate location shifts between groups.
Differences between categorical variables will be examined
via the chi-square test. The Kruskal-Wallis test will be used
to assess differences in more than two independent sam-
ples. To evaluate the predictive power of variables regard-
ing the criterion “consolidation” adjusting for potentially
clinically relevant covariates logistic regression models will
be set up and constructed via backwards selection. Analo-
gous to our previous studies [44–46], predictive perform-
ance will be assessed through estimation of the models
AUC (area under the curve) of the corresponding ROC
curve and AIC (Akaike information criterion). Continuous
variables will be expressed as absolute mean concentrations
± SD (standard deviation) and the level of significance (α) is
set at 5%.
Table 1 Structure of clinical and radiological follow-up
Pre-op 2 D post-op 6 W post-op 3 M post-op 6 M post-op 9 M post-op 12 M post-op 24 M post-op
Clinical examination x x x x x x x x
X-ray x x x x x x x x
DCE-MRI x
CT x
CEUS x x
Questionnaire (SF-12) x x x x
Laboratory work x x x x x x x x
Abbreviations: pre-op pre-operative, post-op post-operative, D days, W weeks, M months, DCE-MRI dynamic contrast-enhanced MRI, CT computer tomography,
CEUS contrast-enhanced ultrasound, SF-12 12-item Short Form health survey
Tanner et al. Trials  (2018) 19:299 Page 5 of 9
Sample size determination
Currently, there are no comparable studies available in the
academic literature. In order to determine the necessary
sample size data from a previous study was utilized (Au-
thor: Haubruck P, Tanner M, Vlachopoulos W, Hagels-
kamp S, Miska M, Ober J, Fischer C, Schmidmaier G.
Title: Comparison of the clinical effectiveness of Bone
Morphogenic Protein (BMP) -2 and -7 in the adjunct
treatment of lower limb non-unions: a matched pair ana-
lysis. Submitted 2018). In this study, a similar patient col-
lective suffering from non-unions of the same anatomical
region being treated with Masquelet therapy were evalu-
ated regarding their osseous consolidation. Based on our
previous study we performed the sample size calculation
for the binary-outcome non-inferiority trial in R [41] using
the package “‘SampleSize4ClinicalTrials” by Hongchao
Qi. Additionally, assuming an alpha level of .05 and a
power of .90 as well as an equal number of subjects
in the experimental and control groups we estimated
that 50 patients in total (25 patients each group) to
be required. Intervention group sizes will match this
determined sample size.
Discussion
This study aims to investigate into the non-inferiority of
the clinical effectiveness of BaG (S53P4) as a bone graft
substitute in Masquelet therapy compared to the stand-
ard Masquelet therapy using autograft.
BaG has been established in previous case series and in
vivo animal studies, but not yet in RCTs as a promising bio-
material due to both its osteostimulative, osteoconductive
(serving as a scaffold for bone formation in vivo) and anti-
microbial properties [33]. In particular, after implantation a
surface reaction occurs, resulting in formation of a calcium
phosphate layer [33, 47]. Release of various ions increases
local pH and osmotic pressure, then a silica gel layer is
formed on the surface of the biomaterial and amorphous
calcium phosphate precipitates on this layer [33]. There-
after, crystallization to natural hydroxyapatite occurs, which
starts the activation of osteoblasts and initiates the forma-
tion of new bone [33, 48]. During this process, new bone is
constituted, the BaG absorbed and the antibacterial micro-
environment maintained due to a persistently increased pH
[33]. Hence, BaG as an artificial bone substitute might con-
tribute to successful non-union treatment by both
Fig. 2 Study process schedule (according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines)
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osteostimulative bone regeneration and prevention of an in-
fection via its antimicrobial properties. Furthermore, im-
plantation of BaG prevents the surgical intervention
necessary for harvesting of the ABG and, therefore, might
contribute to a lower complication rate and lower comor-
bidities associated with Masquelet therapy. A potential limi-
tation of the planned study lies in the utilization of different
methods of osteosynthesis that might influence the out-
come of non-union treatment. However, a study by Vallier
et al. compared the results between plate fixation and intra-
medullary nail fixation of tibial shaft fractures. The authors
concluded that rates of union, infection and secondary pro-
cedures were similar [49]. In addition, all included patients
will employ the same post-operative weight-bearing pattern.
Therefore, we believe that the influence of different
methods of osteosynthesis on the findings of the planned
study to be minimal. The results from the current study
will help evaluate the clinical effectiveness of this promising
biomaterial in non-union therapy. Our hypothesis is that
S53P4-type BaG will have the same rate of consolidation as
autologous bone when used in the second step of the Mas-
quelet therapy. Furthermore, we assume that the rate of
perioperative infection in patients treated with S53P4-BaG
will be reduced compared to the control group and that pa-
tients of the study group will have fewer post-operative
complications and morbidities. The results of the study
should, therefore, help investigate the potential benefits and
limitations regarding the use of S53P4-BaG in Masquelet
therapy. Data from the study will increase the knowledge
about S53P4-BaG as a bone graft substitute as well as iden-
tify patients who might benefit from Masquelet therapy
using this type of BaG and those who are more likely to fail.
Ultimately, the current study might contribute to an im-
provement in the quality of non-union treatment.
Trial status
The RCT recruitment and surgical treatment are planned
from April 2018 until April 2020. Follow-up will be con-
ducted over 24 months for each included patient. Data
analysis and evaluation will be performed after 12 months
and 24 months. The study will be halted if the study group
shows severe disadvantages after 12 months. Final results
of this study will be published.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 119 kb)
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